Download PDF
Der Nuklearmediziner 2004; 27(4): 278-287
DOI: 10.1055/s-2004-832453
© Georg Thieme Verlag Stuttgart · New York

PET und PET/CT - Stellenwert beim Lungenkarzinom

PET and PET/CT - Clinical Value in Lung CancerH. C. Steinert1
  • 1Klinik und Poliklinik für Nukearmedizin, Departement Medizinische Radiologie, Universitätsspital Zürich, Schweiz
Further Information

Publication History

Publication Date:
14 February 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das präoperative Staging beim Lungenkarzinom ist entscheidend für die Prognose und die Therapieentscheidung. Ziel dieser Übersicht ist die Darstellung der FDG-PET und der CT als synergistische Verfahren. Zur Planung der Operation und der Strahlentherapie ist die präzise Definition der Tumorausdehnung erforderlich. Durch die integrierte PET/CT können die Tumorinfiltration in die Umgebung und kleinste Metastasen exakt lokalisiert werden. In der Übersicht werden die Anwendungen der PET und PET/CT beim nicht-kleinzelligen Bronchuskarziom, beim kleinzelligen Bronchuskarziom und beim malignen Pleuramesotheliom vorgestellt.

Abstract

Preoperative staging of lung cancer is essential for prognosis and management. The aim of this overview is to present the synergistic effects of FDG-PET and CT. For planning surgery and planning radiation treatment the precise definition of the tumor extend is essential. Integrated PET/CT scanning enables the exact localization of tumor infiltration into surrounding tissue and of small metastases. In this overwiew the applications of PET and PET/CT in non-small-cell lung cancer, small-cell lung cancer and malignant pleural mesothelioma are presented.

Schlüsselwörter

Lungenkarzinom - PET - PET/CT - Bildfusion - FDG

Key words

Lung cancer - PET - PET/CT - image fusion - FDG

Literatur

  • 1 Antoch G, Jentzen W, Freudenberg L S. et al . Non-small cell lung cancer: dual modality PET/CT in preoperative staging.  Radiology. 2003;  229 784-789
    PubMedGoogle Scholar
  • 2 Ciernik I F, Dizendorf E, Baumert B. et al . Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT: a feasibility study.  Int J Radiat Oncol Biol Phys. 2003;  57 853-863
    CrossrefPubMedGoogle Scholar
  • 3 Chin B B, Wahl R. 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.  Gut. 2003;  52 23-29
    PubMedGoogle Scholar
  • 4 Dwamena B A, Sonnad S S, Angobaldo J O, Wahl R L. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT.  Radiology. 1999;  213 530-536
    PubMedGoogle Scholar
  • 5 Erasmus J J, Patz E F, Mc Adams H P. et al . Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.  AJR. 1997;  168 1357-1362
    PubMedGoogle Scholar
  • 6 Gupta N C, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using flurine-18-FDF and PET.  J Nucl Med. 1996;  37 943-948
    PubMedGoogle Scholar
  • 7 Hany T F, Steinert H C, Goerres G W, Buck A, von Schulthess G K. Improvement of diagnostic accuracy of PET imaging using a high performance in-line PET-CT system: preliminary results.  Radiology. 2002;  225 575-581
    CrossrefPubMedGoogle Scholar
  • 8 Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch C M. Metaanalyse zum Stellenwert der Positronen-Emissions-Tomographie mit F-18-Fluorodesoxyglukose (FDG-PET) bei Lungentumoren.  Pneumologie. 2001;  55 367-377
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Kamel E, Goerres G W, Burger C, von Schulthess G K, Steinert H C. Detection of recurrent laryngeal nerve palsy in patients with lung cancer using PET-CT image fusion.  Radiology. 2002;  224 153-156
    PubMedGoogle Scholar
  • 10 Kamel E, Zwahlen D, Wyss M T, Stumpe K DM, von Schulthess G K, Steinert H C. Whole-body 18F-FDG PET improves the management of patients with small-cell lung cancer.  J Nucl Med. 2003;  44 1911-1917
    PubMedGoogle Scholar
  • 11 Kernstine K H, McLaughlin K A, Menda Y. et al . Can-FDG PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?.  Ann Thorac Surg. 2002;  73 394-402
    CrossrefPubMedGoogle Scholar
  • 12 Lardinois D, Weder W, Hany T F. et al . Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.  N Engl J Med. 2003;  348 2500-2507
    CrossrefPubMedGoogle Scholar
  • 13 Nestle U, Walter K, Schmidt S. et al . 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis.  Int J Radiat Oncol Biol Phys. 1999;  44 593-597
    CrossrefPubMedGoogle Scholar
  • 14 Marom E M, McAdams H P, Erasmus J J. Staging non-small cell lung cancer with whole-body PET.  Radiology. 1999;  212 803-809
    CrossrefPubMedGoogle Scholar
  • 15 Mountain C F. The International System for Staging Lung Cancer.  Semin Surg Oncol. 2000;  18 106-115
    CrossrefPubMedGoogle Scholar
  • 16 Pieterman R M, van Putten J WG, Meuzelaar J J. et al . Preoperative staging of non-small-cell lung cancer with positron-emission tomography.  N Engl J Med. 2000;  343 254-261
    CrossrefPubMedGoogle Scholar
  • 17 Santos Dellea M M, Burger C, Hany T. et al . Response evaluation in malignant pleural mesothelioma (MPM) with FDG-PET/CT.  Eur J Nucl Med Mol Imag. 2004;  31 408
    PubMedGoogle Scholar
  • 18 Schneider D B, Clary-Macy C, Challa S. et al . Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural MPM.  J Thorac Cardiovasc Surg. 2000;  120 128-133
    CrossrefPubMedGoogle Scholar
  • 19 Steinert H C, Hauser M, Allemann F. et al . Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling.  Radiology. 1997;  202 441-446
    PubMedGoogle Scholar
  • 20 Steinert H C, Goerres G, Roudas M, Weder W, Lardinois D. Detection of a new solitary lesion by whole-body FDG PET-CT in patients with lung cancer: frequency and pathologic correlation.  J Nucl Med. 2004;  45 P376
    PubMedGoogle Scholar
  • 21 Strauss L G. Fluorine-18-deoxyglucose and false-positive results: a major problem in the diagnosis of oncological patients.  Eur J Nucl Med. 1996;  23 1409-1414
    CrossrefPubMedGoogle Scholar
  • 22 Vansteenkiste J F, Stroobants S G, De Leyn P R. et al . Lymph node staging in non-small cell lung cancer with FDG PET scan: a prospective study on 690 lymph node stations from 68 patients.  J Clin Oncol. 1998;  16 2142-2149
    PubMedGoogle Scholar
  • 23 Van Tinteren H, Hoekstra O, van den Bergh J HAM. et al . Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.  Lancet. 2002;  359 1388-1392
    CrossrefPubMedGoogle Scholar
  • 24 Weder W, Schmid R, Bruchhaus H, Hillinger S, von Schulthess G K, Steinert H C. Detection of extrathoracic metastases by positron emission tomography in lung cancer.  Ann Thorac Surg. 1998;  66 886-893
    CrossrefPubMedGoogle Scholar
  • 25 Weyant M J, Flores R M. Imaging of pleural and chest wall tumors.  Thorac Surg Clin. 2004;  14 15-23
    PubMedGoogle Scholar
  • 26 Zhuang H, Hickeson M, Chacko T K. et al . Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules.  Clin Nucl Med. 2002;  27 628-632
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. Hans C. Steinert

Klinik und Poliklinik für Nuklearmedizin · Departement Medizinische Radiologie · Universitätsspital Zürich

Rämistrasse 100

8081 Zürich

Schweiz

Phone: +41/1/2 55/34 42

Fax: +41/1/2 55/44 14

Email: hans.steinert@usz.ch